SLC5A2 and chronic kidney disease: Several large cohort studies and randomized controlled trials (RCTs) have demonstrated favorable cardiovascular outcomes associated with sodium glucose cotransporter-2 inhibitors (SGLT2i) in patients with diabetes or CKD [13–19].